Skip to Content
Merck
CN
All Photos(2)

Documents

Safety Information

HBNMAG-51K

Millipore

MILLIPLEX® Human Bone Magnetic Bead Panel - Bone Metabolism Multiplex Assay

The analytes available for this multiplex kit are: ACTH, DKK-1, FGF-23, IL-1β, IL-6, Insulin, Leptin, Osteocalcin, OPN - Osteopontin, Osteoprotegerin, PTH, SOST, TNF-α.

Synonym(s):

human bone metabolic biomarkers immunoassay panel, luminex human bone metabolism multiplex assay, millipore human bone metabolic biomarkers multiplex kit

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

200

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 82-97%
standard curve range: 0.24-1,000 pg/mL
(TNFα)
standard curve range: 1-3,000 pg/mL
(IL-1β)
standard curve range: 1-6,000 pg/mL
(ACTH & IL-6)
standard curve range: 146-600,000 pg/mL
(OC)
standard curve range: 24-100,000 pg/mL
(SOST)
standard curve range: 37-150,000 pg/mL
(FGF-23)
standard curve range: 49-200,000 pg/mL
(Leptin)
standard curve range: 5-20,000 pg/mL
(DKK-1)
standard curve range: 5-20,000 pg/mL
(PTH)
standard curve range: 61-250,000 pg/mL
(Insulin)
standard curve range: 7-30,000 pg/mL
(OPG)
standard curve range: 98-400,000 pg/mL
(OPN)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Related Categories

General description

Bone metabolism is the dynamic process of ongoing bone deposition and resorption, controlled by osteoblasts, osteocytes, and osteoclasts. While osteoblasts and osteocytes (osteoblasts surrounded by matrix) are responsible for bone deposition, osteoclasts are responsible for bone resorption. Both are required to maintain bone structure, as well as an adequate supply of calcium. To maintain this metabolic balance these cells rely on complex signaling pathways involving hormones and cytokines to achieve the appropriate rates of growth and differentiation. The disruption of bone metabolism results in such disease as osteoporosis, osteoarthritis, rheumatoid arthritis, chronic kidney disease and bone metastases.

MILLIPLEX® Human Bone Magnetic Bead kit is to be used for the simultaneous quantification of any or all of the following analytics in human plasma, serum or tissue/cell lysate and culture supernatant samples: Adrenocorticotropic Hormone (ACTH), Dickkopf-1 (DKK1), IL-6, Insulin, Leptin, TNFα, Osteopotegrin (OPG), Osteocalcin (OC), Osteopontin (OPN), Sclerostin (SOST), IL-1β, Parathyroid Hormone (PTH) and FGF-23. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Bone

Specificity

Cross Reactivty
No cross reactivity between the antibodies for an analyte in this panel were observed.

Application

  • Analytes: ACTH, DKK-1, FGF-23, IL-1β, IL-6, Insulin, Leptin, Osteocalcin (OC), Osteopontin (OPN), Osteoprotegerin (OPG), PTH, Sclerostin (SOST), TNFα
  • Recommended Sample Type: Human serum, plasma, and cell/tissue culture supernatants or extracts
  • Recommended Sample Dilution: 25 μL per well of d1:2 diluted serum or plasma; cell/tissue culture samples may be used neat or diluted in appropriate control medium
  • Assay Run Time: Overnight (16–18 hours) at 2-8°C or 2 hours at room temperature (20-25°C)
  • Research Category: Metabolism
  • Research Subcategory: Bone

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Linkage

Replaces: HBN1B-51K

Other Notes

Please contact Technical Service for linearity of dilution.
Sensitivity: See kit protocol for individual analytes sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sharon M Moe et al.
Circulation, 132(1), 27-39 (2015-06-11)
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet
Edward R Smith et al.
Scientific reports, 7(1), 5686-5686 (2017-07-20)
Calciprotein particles, nanoscale aggregates of insoluble mineral and binding proteins, have emerged as potential mediators of phosphate toxicity in patients with Chronic Kidney Disease. Although existing immunochemical methods for their detection have provided compelling data, these approaches are indirect, lack
Nigel Kurgan et al.
Frontiers in endocrinology, 11, 531926-531926 (2020-12-29)
In adults, excess adiposity has been associated with low-grade, chronic inflammation and compromised bone health, but less is known about these linkages in children. The purpose of this study was to compare the circulating levels of inflammatory cytokines, adipokines, osteokines
Chiara Giannasi et al.
International journal of medical sciences, 16(1), 23-32 (2019-01-22)
Bisphosphonates (BPs) represent the first-line treatment for a wide array of bone disorders. Despite their well-known action on osteoclasts, the effects they induce on osteoblasts are still unclear. In order to shed light on this aspect we evaluated the impact
Paolo Giannoni et al.
Haematologica (2020-08-29)
Bone skeletal alterations are no longer considered a rare event in Chronic Lymphocytic Leukemia (CLL), especially at more advanced stages of the disease. This study is aimed at elucidating the mechanisms underlying this phenomenon. Bone marrow stromal cells, induced to
View All Related Papers

Related Content

MILLIPLEX® PLEXpedition Multiplex Biomarker Screening Panel

Simplify protein biomarker discovery with the MILLIPLEX® PLEXpedition 115-Plex Multiplex Screening Panel. Effortlessly screen cytokines and other markers with Luminex® technology.

Multiplexing Tips & Tricks

UnEnhance research with MILLIPLEX® multiplexing tips, industry guidance, and one-day assays for limited lab time.

Multiplexing Metabolic Syndrome Biomarkers | MILLIPLEX® Assays

Multiplex immunoassays, such as MILLIPLEX® multiplex metabolic assays, are critical in metabolic syndrome research because they provide a full picture of the different conditions related to it, like diabetes and obesity, as well as save time and sample volume.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service